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Original Article
Growth Hormone Receptor and IGF-I Receptor
Immunoreactivity During Orthodontic Tooth Movement in the
Prednisolone-Treated Rat
C.K.L. Ong MDSca; B.K. Joseph MSc, BDS, MDSc, PhDb; M.J. Waters BSc, PhD, DScc;
A.L. Symons MDS, PhD, GCEd
Abstract: Bone remodeling during tooth movement is regulated by local and systemic factors. Two
regulators of bone metabolism are growth hormone (GH) and insulin-like growth factor-I (IGF-I). Their
effects are mediated via binding to GH receptor (GHR) and IGF-I receptor (IGF-IR) in target tissues.
Corticosteroids may affect the activity of these growth factors. This study examined the effect of prednis-
olone on GHR and IGF-IR expression in dental tissues following orthodontic tooth movement. The cor-
ticosteroid-treated group (N 5 6) was administered prednisolone (1 mg/kg) daily and the control group
(N 5 6) received equivalent volumes of saline. An orthodontic force (30 g) was applied to the maxillary
first molar. Animals were sacrificed 12 days postappliance insertion. Sagittal sections of the first molar
were stained for GHR and IGF-IR immunoreactivity. GHR and IGF-IR cell counts were elevated following
appliance-treatment. Orthodontic tooth movement appeared to up-regulate GHR and IGF-IR immunore-
activity, but this up-regulation was reduced following prednisolone treatment. The suppression of GHR
and IGF-I immunoreactivity in steroid-treated animals infers the mechanism whereby bone resorption and
deposition, necessary for orthodontic tooth movement, may be inhibited by prednisolone. However, at 12
days postappliance insertion, no difference in orthodontic tooth movement was observed following low-
dose prednisolone treatment. (Angle Orthod 2001;71:486–493.)
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INTRODUCTION
Orthodontic tooth movement evokes a cascade of cellular
responses within the enveloping alveolar bone and peri-
odontal ligament (PDL). Bone remodeling and the metab-
olism associated with this tooth movement are regulated by
a large number of local and systemic growth factors. The
widespread use of therapeutic corticosteroids today raises
concerns with regard to their effects on the production and
activity of these growth factors during orthodontic tooth
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movement. The side effects associated with the long-term
use of prednisolone therapy include disturbances in min-
eralized tissue metabolism and wound healing, and sup-
pression of somatic growth, chondrogenesis and osteogen-
esis.1–3
Two major regulators involved in bone metabolism are
growth hormone (GH) and its mediator, insulin-like growth
factor-I (IGF-I). GH is an important regulator of postnatal
skeletal growth and development and promotes stem-cell
differentiation and proliferation. It acts both indirectly and
directly to influence bone and chondrocyte cell function and
differentiation.4,5 The indirect actions of GH are mediated
by locally and possibly hepatic produced IGF-I.6 GH has
been shown to actively participate in bone remodeling by
stimulating osteoblast formation7 and osteoclastic bone re-
sorption.8
IGF-I has an active role in bone remodeling, and its pro-
duction is GH dependent. IGF-I is potent in assays for the
promotion of growth, development, and functioning of
most tissues.9 It influences osteoblastic function in all stages
of development and increases the replication of cells of the
osteoblastic lineage.10 Osteoclasts actively engaged in bone
resorption have been found to express IGF-I and IGF-I re-
ceptor (IGF-IR) mRNA.11
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Corticosteroids are suggested to disrupt the GH/IGF-I
axis by suppressing GH levels and increasing total IGF-I
levels 12 and may deplete the bone marrow stroma of os-
teogenic precursors.13 High concentrations of steroids cause
a decrease in protein, RNA, and DNA synthesis in bone
cells.14–17. In addition, corticosteroids alter the expression of
a number of genes in osteoblastic cells, including those for
growth factors and receptors.10 GH and IGF-I have specific
receptors to which they bind and interact.18,19 GH receptor
(GHR) expression in the periodontium is initially reduced
and subsequently enhanced during orthodontic tooth move-
ment 20 and during tooth eruption alveolar bone osteoblasts
and osteoclasts demonstrate GHR immunoreactivity.21,22
Steroids have also been shown to down-regulate GHR, re-
sulting in a reduction of bone formation in vivo.10,23 Ortho-
dontic tooth movement requires a functioning bone metab-
olism that permits efficient bone resorption and deposition
following the application of a force. Therefore, the aim of
this study was to examine the effect of low-dose prednis-
olone treatment on the expression of GHR and IGF-IR
around the distal root of the maxillary first molar during
orthodontic tooth movement using a well-established rat
model.
MATERIALS AND METHODS
Animals and prednisolone treatment
Twelve 9-week-old male Wistar rats (average weight
270.5 g) obtained from the Central Animal Breeding
House, University of Queensland, Brisbane, Australia, were
used in this study. Animals were examined in two groups:
experimental (n56) and control (n56). The Institutional
Ethics Committee granted ethical clearance and the study
followed the guidelines prescribed for animal experimen-
tation by the National Health and Medical Research Coun-
cil of Australia. Animals were acclimatized for 5 days in
plastic cages (two per cage) with a standard 12-hour light/
dark cycle. They were fed a diet of finely ground laboratory
food (Rat and Mouse Cubes, Norco, Brisbane, Australia)
ad libitum. Body weights of all rats were measured daily.
The experimental group was administered daily doses of 1
mg/kg oral prednisolone in saline (Panafcortelone 1t, Fi-
sons Pty Ltd, Sydney, Australia), using a stomach tube, for
a 12-day induction period and during the experimental pe-
riod. The control group was administered an equivalent vol-
ume of saline (Sodium Chloride 0.9%, Astra Pharmaceu-
ticals Pty Ltd, Australia). The dose of 1 mg/kg prednisolone
has been used in our laboratory previously.24 It is within
recommended therapeutic levels for rats and is associated
with anti-inflammatory and some immunosuppressive ef-
fects.25
Orthodontic appliance treatment
Following acclimatization, an orthodontic appliance was
inserted on the maxillary left first molar, and a mesially
directed force of 30 g was applied. The orthodontic appli-
ance consisted of a stretched closed coil spring (0.008 inch
3 0.032 inch Elgiloy spring, Rocky Mountain Dental Prod-
ucts Co, USA) ligated between the maxillary left first molar
and 2 maxillary central incisors as previously described.24
The molar on the right side was used as the nonappliance
control. The magnitude of tooth movement was determined
by measuring the relative separation between the first and
second maxillary molar using vernier calipers with sharp-
ened tips inserted into occlusal pits.24 The distance between
the mesial occlusal pits on the first and second molars was
measured intraorally before appliance insertion and imme-
diately after sacrifice. Measurements were performed by the
same operator (CKLO) and were repeated five times for
each side of the maxilla.
Rats were sedated during appliance insertion using sub-
cutaneous injections of fentanyl citrate/fluanisone and mid-
azolam (Sublimaze & Hypnovel) 0.15–0.2 mL per 100 g
body weight. One animal in the nonsteroid control group
died from complications associated with the use of these
sedatives.
Histological preparation
At 12 days postappliance insertion, rats were euthanised
using carbon dioxide asphyxiation. Maxillae were imme-
diately removed and dissected into halves, fixed in Bouin’s
solution (1.2% picric acid, 10% formaldehyde, and 5% gla-
cial acetic acid) for 24 hours and demineralized in 0.25 M
ethylenediaminetetraacetic acid (EDTA) (10%, pH 7.2) at
48C for 14 days. Paraffin sagittal sections were prepared
(parallel to the long axis of the first molar to a thickness
of 5 mm) and mounted on 3-aminopropyltriethoxysilane
coated glass slides. Sections closest to the midline of the
crown, which contained roots, radicular tissue, and pulp,
were examined. Two serial sections from each animal were
stained for GHR and two serial sections for IGF-IR ex-
pression.
Immunohistochemistry
Deparaffinized sections were incubated with the appro-
priate antibody and processed for determining the distri-
bution of GHR and IGF-1R. Staining was carried out using
the specific 3-layered streptavidin peroxidase technique to
detect bound antibody, as described previously in detail for
rat tissues for GHR26–28 and IGF-IR29 using well-character-
ized antibodies.
Briefly, sections were deparaffinized, hydrated, and in-
cubated in 0.03% hydrogen peroxide in phosphate buffered
saline (pH 7.3) for 10 minutes at 258C to block endogenous
peroxidase. Nonspecific protein binding was eliminated
with rabbit serum for 1 hour at 258C. They were then in-
cubated with antibody to GHR or IGF-IR overnight at 48C.
Binding was identified by the addition of biotin conjugated
anti-immunoglobulin followed by streptavidin horseradish
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FIGURE 1. Boxes representing cell count sites on the distal root
(DR): (1) along the alveolar bone (B) margin; (2) in the central region
of the periodontal ligament; and (3) along the distal root surface.
peroxidase. A substrate containing tris HCL, 3,3-diaminob-
enzidine and peroxide was used to develop the slide sec-
tions. Slides were counterstained with Mayer’s haematox-
ylin, dehydrated, and mounted. All incubations were made
in humidified chambers. Controls included a negative con-
trol (omitting the primary antibody) and a positive control
(rat liver tissue for GHR and rat digestive tract for IGF-
IR).
Histological analysis
The 22 hemimaxillae harvested from the six steroid-
treated (ST) and five nonsteroid-treated (NST) control an-
imals were divided into the following 4 groups for histo-
logical examination: (1) no-steroid, no-appliance controls
(NNA) (2) no-steroid, appliance-treated controls (NAP), (3)
steroid-treated, no-appliance (SNA) animals, and (4) ste-
roid- and appliance-treated (SAP) animals. Histomorphom-
etry was performed on the regions surrounding the distal
root (coronal one-third) of the first molar using a light mi-
croscope. Cell counts were limited to the mesial and distal
sides of the distal root, corresponding to compression and
tension sides, respectively, in the appliance groups (Figure
1). Cell counts were made with a precalibrated 10310-grat-
icule-eyepiece micrometer (Olympus, 24 OC-M, 10/10 SQ,
Tokyo, Japan) mounted on a light microscope under 4003
magnification. Total cell numbers were counted from 10
adjacent small squares (area 24.5 m2) orientated vertically
along the surface of the alveolar bone and cementum, and
the PDL.
GHR and IGF-IR immunoreactive cells stained brown.
The main immunoreactive cell types counted along the al-
veolar bone surface and root surface were mononuclear
blast-like and multinucleated clast-like cells. Within the
PDL, fibroblast-like, mononuclear, and multinucleated
clast-like cells were identified as being positively stained.
The GHR and IGF-IR positive cell counts were performed
on two serial sections from each animal within the four
groups (NNA, NAP, SNA, SAP). Each section was mea-
sured twice, yielding four measurements from which the
average value for each animal was derived. The combined
values for each animal within a particular group were then
averaged to yield the group mean value. The differences in
the mean values for each of the four groups were compared
using one-way analysis of variance (ANOVA) with signif-
icance at P , .05.
RESULTS
Animal health and measurement error
Food and water consumption appeared to be unaffected
by the presence of an appliance. There was an overall gain
in weight throughout the induction and experimental peri-
ods (controls 24.5 6 6.4 g and steroid-treated 23.4 6 4.0
g) that was not significantly different between the groups.24
There was good to high agreement for measurements un-
dertaken by the one investigator (CKLO). Agreement for
intra-examiner cell counts was not less than 97%.
Tooth movement
All appliance-treated molars showed evidence of tooth
movement, as previously described.29 No significant differ-
ence in the magnitude of tooth movement was present in
controls compared with steroid-treated animals. No tooth
movement was evident on the nonappliance side.
Specificity of immunoreactivity
Incubation of the sections without the primary antibody
for GHR and IGF-IR produced no staining. Positive stain-
ing was clearly evident in liver tissue for GHR and gastric
epithelium for IGF-IR.
Growth Hormone Receptor expression
Cells in the PDL and along the adjacent mineralized tis-
sue surfaces demonstrated immunoreactivity for GHR (Fig-
ure 2). In the appliance groups, multinucleated clast-like
cells were located in resorption lacunae on the root surface
and along the adjacent alveolar bone undergoing remodel-
ing on the compression-side and within the PDL. There was
a variable expression of GHR immunoreactivity among the
multinucleated cells, with some, but not all, clast-like cells
staining positive. The greatest number of GHR-positive
cells was found within the PDL. Most positively stained
cells in this region were mononuclear and fibroblast-like.
Cells staining positive along the alveolar bone were oste-
oblast-like cells. Osteocytes stained negative in all speci-
mens. Along the root surfaces, cells staining positive ap-
peared to be cementoblasts.
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FIGURE 2. Histological sections from the mesial surface of the distal root of the first molar showing GHR immunoreactivity in the NAP group:
(a) osteoblasts (arrowed), (b) cementoblasts (arrowed), (c) osteoclasts (arrowed) located in resorption lacunae on the root (R) surface; and
IGF-IR immunoreactivity in the NAP group: (d) osteoclasts (arrowed) located in resorption lacunae on the root (R) surface. Alveolar bone (A),
cementum (C), periodontal ligament (P) and distal root (R). Bar represents 50 mm.
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FIGURE 3. Mean GHR cell counts along the alveolar bone and root surfaces and PDL. (Mean values and standard deviations). SAP compared
with NAP, P , .05, except for the root surface on the mesial aspect.
Generally, orthodontic tooth movement enhanced GHR
immunoreactivity and steroid treatment reduced GHR im-
munoreactivity (Figure 3). In all the areas investigated ex-
cept for the root surface on the mesial aspect, there were
significantly fewer GHR-positive cells associated with the
SAP group compared with the NAP group (P , .05). The
SNA group expressed the least number of GHR positive
cells in all areas.
Nonappliance groups expressed fewer GHR-positive
cells compared with appliance groups in all areas examined
except for the mesial root surface where there were no sta-
tistical differences between the NNA and NAP groups and
between the SNA and SAP groups.
IGF-I- Receptor expression
Cell types expressing IGF-IR were similar to those that
expressed GHR (Figure 2). The greatest numbers of posi-
tive cells were located in the PDL. These cells appeared to
be fibroblast-like and mononuclear cells. Osteoblast-like
cells along the alveolar bone surface and cementoblasts
were positively stained. Multinucleated osteoclast-like cells
were variable in expression of IGF-IR and positive cells
were located on the resorbing alveolar bone, in resorption
defects on the root surface, and in the PDL.
The pattern of IGF-IR immunoreactivity and staining in-
tensity was similar to that noted for GHR (Figure 4). Co-
localization of GHR and IGF-IR was variable and random.
The positive cell counts were generally fewer for IGF-IR
compared with GHR, and the significant differences be-
tween the groups for IGF-IR were less than for GHR.
As for GHR, steroid-treatment reduced the overall num-
ber of IGF-IR positive cells in tissue sections. The SAP
group had significantly fewer IGF-IR positive cell numbers
in all cell-count areas compared with the NAP group (P ,
.05) except on the tension side alveolar bone and root areas.
The SNA group showed consistently fewer positive cells in
all areas investigated compared with NNA and NAP groups
(P , .05).
Appliance groups showed a variable increase in positive
IGF-IR cell counts compared with nonappliance groups.
Along the mesial alveolar bone surface, the NAP group had
more IGF-IR positive cell numbers compared with the
NNA group (P 5 .041). The SAP group expressed greater
IGF-IR positive cell numbers compared with the SNA
group along the mesial root surface (P 5 .028), mesial PDL
(P 5 .028), and distal alveolar bone surface (P 5 .024).
There were no significant differences in IGF-IR positive
cell numbers between the NNA and NAP groups and be-
tween the SNA and SAP groups along the distal root sur-
face and distal PDL.
DISCUSSION
In this study, administration of 1 mg/kg prednisolone had
a suppressive effect on cell immunoreactivity for GHR and
IGF-IR in most dental and paradental tissues. Tooth move-
ment induced by an orthodontic appliance upregulated the
immunoreactivity for GHR and IGF-IR to varying degrees
but suppression by prednisolone was still evident. No dif-
ference in the magnitude of tooth movement was observed
in the prednisolone-treated group.
The rat model adapts well to orthodontic forces and max-
imum deformation of molar alveolar tissues is achieved at
force levels between 20–40 g, beyond which there is no
further deformation and no further increase in tooth move-
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FIGURE 4. Mean IGF-1R cell counts along the alveolar bone and root surfaces, and PDL. (Mean values and standard deviations). SAP
compared with NAP, P , .05, except for the bone and root surface on the distal aspect. SNA had significantly fewer positive-cells compared
with NNA and NAP, P , .05.
ment.30 The force level of 30 g selected for the present
study produces effective orthodontic tooth movement with-
out any adverse effects.24 The duration of appliance wear
was based on previous studies which showed that 10–14
days are required for one complete bone remodeling cycle
to take place.30–32 Bone resorption activity peaks on the
compression side 7 days after appliance activation and a
peak rate of osteoclastic activity occurs after 7 to 8 days of
appliance therapy.30 This is followed by a second wave of
osteoclastic activity towards the end of appliance decay at
days 12–14. Bone turnover at pressure and tension sites
remains elevated for up to 16 days following activation
although the orthodontic forces have substantially de-
cayed.31
The present study noted a pattern of overall reduction in
cellular GHR immunoreactivity associated with the steroid-
treated animals during orthodontic tooth movement. Simi-
larly, methylprednisolone (400 mg/day) administered orally,
has been shown to reduce hepatic GH binding and mark-
edly suppress plasma GH binding protein and GHR ex-
pression.11 Glucocorticoids are thought to decrease tissue
sensitivity to GH by decreasing the number of available
GHRs.33 This is supported by the observation of reduced
GHR immunoreactivity in steroid-treated animals noted in
the present study. However, glucocorticoids do not always
appear to down-regulate GHR and dexamethasone has been
shown to increase GHR expression in cultured rat pancre-
atic islets.34 In contrast, our in vivo data indicated that the
GHR was down-regulated by continuous glucocorticoid
treatment in a variety of tooth- and bone-forming cells dur-
ing orthodontic tooth movement. At 12–14 days after the
application of an orthodontic force, osteoclast activity
peaks31 and GHR immunoreactivity in periradicular tissues
is also elevated.20 Suppression of GHR and IGF-IR im-
munoreactivity in cells associated with orthodontic tooth
movement may indicate that cell function is altered by
prednisolone treatment, which may arise from a lack of
available precursors.28,35
Endocrine factors which regulate the expression of GHR
include GH, insulin, IGF-IR, thyroxine and sex steroids.19
GHR mRNA has been shown to be present in most tissues
in the rat and correlates with ligand binding.36 The control
of GHR gene expression is complex, involving at least sev-
en alternative promoters and is dependent on tissue specific,
developmental, hormonal, and nutritional factors.19 Previ-
ous studies reported the expression of GHR in cells show-
ing morphological signs of differentiation and prolifera-
tion.37,38 The expression of GHR was linked to the func-
tional state of the various cell populations during odonto-
genesis, in particular, the onset of cytodifferentiation. 4,5
Similarly, cellular IGF-IR expression was reduced in ste-
roid-treated animals. These findings differ from those of
Bennett et al.39 who conducted experiments on cultured rat
bone cells from foetal calvaria in which IGF-IR numbers
were increased by exposure to dexamethasone. However,
the latter effect of increased receptor numbers was only
observed in conditions of overall increased cell numbers.
Receptor expression may vary with stage of development
in cells from foetal and mature bone, and in vivo compared
with in vitro studies. Indeed, in other studies cortisol has
been shown to down-regulate IGF-IR mRNA levels and
IGF-IR expression.40,41
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IGF-I in plasma and other body fluids can be bound to
IGF binding proteins (IGFBP). The role of IGFBPs in bone
cell function is unclear at present. These carrier proteins are
believed to determine the bioavailability of IGF-I and to
modulate its biologic actions.9,42 Unfortunately, the exact
mechanism by which these binding proteins regulate or
modulate the interaction of IGF with their receptors is still
unclear. They are believed to function in several ways: by
binding to IGF-I and decreasing the bioavailability of IGF-
I; by enhancing the binding of IGF-I to its receptor, thereby
potentiating its activity in skeletal tissues; by controlling
the transport of the IGF to specific cell types; by direct IGF-
I independent actions on target cells; and by increasing the
half-life of IGF-I in serum.4,6,43 Dexamethasone has been
shown to suppress IGFBP in rat osteoblast-like cells44 and
high doses of cortisol have been shown to inhibit the pro-
duction of IGFBP in vitro.43 Since IGF-I is believed to up-
regulate its own receptor,45 and prednisolone decreases IGF-
I production, this may contribute to the loss of IGF-IR ob-
served in the current study.
At 12 days postappliance activation, no difference was
detected in orthodontic tooth movement between control
and prednisolone-treated animals. However, in the rabbit
where a higher dosage of corticosteroid induced osteopo-
rosis, rapid orthodontic tooth movement and increased re-
lapse were observed.46 The ability of corticosteroid to affect
bone metabolism is related to dosage, duration, and the spe-
cific medication. Orthodontic movement in patients with
corticosteroid-induced osteoporosis may require special
consideration. Where osteoporosis is related to increase
bone turnover and the rate of resorption exceeds deposition,
orthodontic tooth movement may be accelerated but relapse
will occur. However, where osteoporosis is related to a de-
pression in resorption and deposition rates, orthodontic
tooth movement may be slowed. While prednisolone-treat-
ment reduced the number of tartrate-resistant acid phospha-
tase-positive cells in the rat PDL during tooth movement
and the incidence of root resorption, no inhibition of tooth
movement was observed.24 The effect of a low-dose pred-
nisolone medication on orthodontic tooth movement may
be negligible or, at the very worst, may slow tooth move-
ment and subsequently require a prolonged retention peri-
od. It is possible that other growth factors and cytokines
compensate for the disturbances in GH and IGF-I activity
induced by prednisolone and allow orthodontic tooth move-
ment to proceed normally.
CONCLUSION
This study reports that a low-dose systemic prednisolone
reduced GHR and IGF-IR immunoreactivity in dental and
paradental tissues in the rat. Although orthodontic tooth
movement upregulated GHR and IGF-IR immunoreactivity
to varying degrees, this effect was relatively reduced in
animals treated with prednisolone. Tooth movement was
not inhibited in rats treated with a low-dose systemic pred-
nisolone.
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